Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Provided By PR Newswire

Last update: Apr 25, 2025

-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple
solid tumors --